October 7, 2015 4:09 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that James Czirr, the Company's Executive Chairman will present at the Robins Equity Research Roundup Conference taking place October 8-10, 2015. Mr. Czirr's presentation, entitled Developing A Therapy for a Silent Epidemic - What Galectin Therapeutics is doing to Develop Treatments for NASH with Liver Cirrhosis and Other Unmet Medical Needs is scheduled for Friday, October 9 at 11:15 a.m. Pacific time. The Robins Equity Research Roundup is presented by Catalyst Research Management Group.An audio replay of Mr. Czirr's presentation will be posted to the Investor Relations section of the company's website the following week.The conference is being held at Skamania Lodge, in the Cascade Range Gorge above the Columbia River. The Robins Equity Research Roundup is a small-cap investor conference focused on introducing new and interesting company equities and their managements to clients and potential shareholders. The audience will include investors and brokers from the region as well as professional money managers from different parts of the country.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.